Zentalis Pharmaceuticals, Inc. (ZNTL)
NASDAQ: ZNTL · Real-Time Price · USD
1.485
-0.045 (-2.94%)
At close: Oct 30, 2025, 4:00 PM EDT
1.510
+0.025 (1.68%)
After-hours: Oct 30, 2025, 5:18 PM EDT
Zentalis Pharmaceuticals Revenue
Zentalis Pharmaceuticals had revenue of $26.87M in the twelve months ending June 30, 2025, down -33.76% year-over-year. In the year 2024, Zentalis Pharmaceuticals had annual revenue of $67.43M.
Revenue (ttm)
$26.87M
Revenue Growth
-33.76%
P/S Ratio
3.95
Revenue / Employee
$161,837
Employees
166
Market Cap
107.12M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 67.43M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
ZNTL News
- 17 days ago - Zentalis Pharmaceuticals Announces Four Azenosertib Posters Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - GlobeNewsWire
- 4 weeks ago - Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - Zentalis Pharmaceuticals, Inc. (ZNTL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary - GlobeNewsWire
- 3 months ago - Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress - GlobeNewsWire
- 4 months ago - Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 months ago - Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress - GlobeNewsWire